Efficacy of butylphthalein injection combined with alteplase thrombolysis in patients with acute cerebral infarction and its impact on Lp-PLA2 and CXCL16 levels

• Published in: American journal of translational research Vol. 16; no. 12; pp. 8054 - 8062
• Main Author: Liu, Aiju
• Format: Journal Article
• Language: English
• Published: United States e-Century Publishing Corporation 01.01.2024
• Subjects: Original; Butalbital injection; alteplase; acute cerebral infarction; Lp-PLA2; CXCL16
• ISSN: 1943-8141; 1943-8141
• DOI: 10.62347/EIPN6922

To evaluate the efficacy of butylphthalein injection combined with alteplase thrombolysis in patients with acute cerebral infarction (ACI) and its effects on lipoprotein-associated phospholipase A2 (Lp-PLA2) and CXC chemokine ligand 16 (CXCL16) levels. A total of 127 ACI patients admitted to Shandong Provincial Third Hospital between March 2020 and June 2023 were included and divided into a butylphthalein group (n = 67) and a control group (n = 60) based on their treatment regimen. All patients received basic treatment. Additionally, the control group underwent intravenous thrombolysis with alteplase, while the butylphthalein group received butylphthalein injection combined with alteplase thrombolysis. Both groups were treated for two consecutive weeks. The overall clinical efficacy rate in the butylphthalein group was significantly higher than that in the control group (P < 0.05). After treatment, cerebral infarction size and National Institutes of Health Stroke Scale (NIHSS) scores were significantly reduced in both groups (both P < 0.05), with greater reductions observed in the butylphthalein group (both P < 0.05). The peak systolic velocity (Vs) of the posterior cerebral, vertebral, and basilar arteries increased significantly in both groups after treatment compared with baseline (all P < 0.05), with higher values in the butylphthalein group (all P < 0.05). The resistance index (RI) of these arteries decreased significantly in both groups after treatment (P < 0.05) and was lower in the butylphthalein group than in the control group (P < 0.05). Serum levels of IL-6, TNF-α, CRP, Lp-PLA2, and CXCL16 were significantly lower after treatment in both groups (all P < 0.05), with greater reductions in the butylphthalein group (all P < 0.05). There was no significant difference in adverse effects between the two groups (P > 0.05). The combination of butylphthalein injection and alteplase intravenous thrombolysis is effective in improving clinical outcomes, reducing neurological deficits, enhancing microcirculation, and lowering serum Lp-PLA2 and CXCL16 levels in patients with ACI. This therapy is worth clinical promotion.